Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Suzuken Co ( (JP:9987) ) has shared an announcement.
Suzuken Co., Ltd. reported its consolidated financial results for the six months ended September 30, 2025, showing a slight increase in net sales by 1.8% to ¥1,219,440 million. However, the company experienced a decline in operating profit by 0.8% and a significant drop in profit attributable to owners of the parent by 19.9%. The company’s equity-to-asset ratio decreased to 34.5% from 36.6% as of March 31, 2025. Despite these challenges, Suzuken maintains its annual dividend forecast and plans to commence dividend payments on December 10, 2025. The financial outlook for the fiscal year ending March 31, 2026, anticipates a 2.8% increase in net sales but a decline in operating and ordinary profit.
The most recent analyst rating on (JP:9987) stock is a Buy with a Yen6800.00 price target. To see the full list of analyst forecasts on Suzuken Co stock, see the JP:9987 Stock Forecast page.
More about Suzuken Co
Suzuken Co., Ltd. is a company listed on the Tokyo, Nagoya, and Sapporo Securities Exchanges, primarily engaged in the pharmaceutical industry. The company focuses on the distribution of pharmaceutical products and related services.
Average Trading Volume: 182,377
Technical Sentiment Signal: Buy
Current Market Cap: Yen337.7B
See more insights into 9987 stock on TipRanks’ Stock Analysis page.